Seelos Therapeutics Inc (SEEL)

[mean gene]

I invested in Apricus @ 2009, Dr. Bassam was at the helm of the company. Vitaros had not been approved and they did not have rights to the U.S. The stock traded at the $5 range pre-split, the hype was all about Vitaros ex-U.S. Rayva and Femprox were where they are now, just in the pipeline. Since then there has been many decision errors made by former and current management that have resulted in mistrust of the management capabilities of delivering on stated goals. The fact remains that U.S. approval of Vitaros is a real possibility and a 20% market share of a 3 billion market equals to 60 million revenue[600m x 10%] at 10% royalty from sales. That would be &7.75 revenue per share and at just 6x earnings equals $46.50 per share. The rayva market in the U.S. alone is at least 100 million and Apricus does not have to split that with any partners, $100 million revenue on 7,733,000 shares is $12.93 revenue per share at a very conservative estimate 6x revenue equals $77.58 per share. This is why I am still here and continue to buy on a regular basis. I may be the biggest fool on this board; however, there are at least a couple of other investors [Denner,Anson] that see potential as I see it. GLTA